GlaxoSmithKline Pharmaceuticals Limited · NSE: GLAXO · BSE: 500660
GlaxoSmithKline Pharmaceuticals
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 03 Aug 2026.
Q1 FY27 · Consolidated
Revenue
938.44₹ Cr
+16.6% vs year ago
Net profit
237.18₹ Cr
+15.7% vs year ago
EPS, basic
14.00₹
+15.7% vs year ago
Net margin
25.3%
−0.2 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 938.44 | +16.6% | 237.18 | +15.7% | 14.00 | 03 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 995.30 | +2.1% | 277.86 | +5.7% | 16.40 | 13 May 2026 |
| Q3 FY26Oct–Dec 2025 | 1,041.26 | +9.7% | 295.62 | +28.6% | 16.54 | 09 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 979.94 | −3.1% | 257.49 | +2.0% | 15.07 | 06 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 805.17 | −1.2% | 205.01 | +12.4% | 12.10 | 01 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 974.37 | +4.8% | 262.87 | +35.2% | 15.52 | 13 May 2025 |
| Q3 FY25Oct–Dec 2024 | 949.42 | +17.9% | 229.88 | +402.8% | 13.57 | 14 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,010.77 | +5.6% | 252.50 | +16.1% | 14.67 | 30 Oct 2024 |
| Q1 FY25Apr–Jun 2024 | 814.65 | +7.0% | 182.33 | +37.9% | 10.76 | 05 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 929.80 | +18.1% | 194.48 | +45.8% | 11.48 | 18 May 2024 |
| Q3 FY24Oct–Dec 2023 | 805.26 | +0.4% | 45.72 | −72.2% | 9.89 | 13 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 956.99 | +4.4% | 217.51 | +12.5% | 12.84 | 13 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 761.66 | +2.2% | 132.25 | +10.9% | 7.04 | 27 Jul 2023 |
| Q4 FY23Jan–Mar 2023 | 787.45 | −2.7% | 133.43 | −89.1% | 7.88 | 18 May 2023 |
| Q3 FY23Oct–Dec 2022 | 802.30 | −1.7% | 164.56 | +9.5% | 9.71 | 08 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 916.87 | −9.2% | 193.42 | −5.3% | 11.42 | 12 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 745.10 | −5.7% | 119.28 | −1.5% | 7.04 | 26 Jul 2022 |
| Q4 FY22Jan–Mar 2022 | 809.63 | −0.5% | 1,219.05 | 85x | 71.96 | 17 May 2022 |
| Q3 FY22Oct–Dec 2021 | 815.92 | −4.8% | 150.35 | −3.9% | 8.88 | 07 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 1,009.87 | +14.8% | 204.24 | +167.1% | 12.06 | 30 Oct 2021 |
| Q1 FY22Apr–Jun 2021 | 789.99 | +21.8% | 121.08 | +9.2% | 7.15 | 27 Jul 2021 |
| Q4 FY21Jan–Mar 2021 | 813.75 | +4.9% | 14.33 | −89.6% | 0.85 | 19 May 2021 |
| Q3 FY21Oct–Dec 2020 | 857.20 | +10.1% | 156.51 | Turned profit | 9.24 | 05 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 879.32 | −0.3% | 76.47 | −84.8% | 4.51 | 29 Oct 2020 |
| Q1 FY21Apr–Jun 2020 | 648.59 | −17.7% | 110.83 | −2.4% | 6.54 | 30 Jul 2020 |
| Q4 FY20Jan–Mar 2020 | 775.80 | — | 138.07 | — | 8.15 | 19 May 2020 |
| Q3 FY20Oct–Dec 2019 | 778.59 | — | (661.16) | — | (39.03) | 04 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 882.02 | — | 502.75 | — | 29.68 | 23 Oct 2019 |
| Q1 FY20Apr–Jun 2019 | 787.97 | — | 113.54 | — | 6.70 | 23 Jul 2019 |
| Q4 FY19Jan–Mar 2019 | 0.00 | — | 0.00 | — | 0.00 | 20 May 2019 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 924.42 | +14.9% | 253.33 | +23.8% | 14.95 | 03 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 989.15 | +2.4% | 274.94 | +5.7% | 16.23 | 13 May 2026 |
| Q3 FY26Oct–Dec 2025 | 1,022.59 | +8.1% | 277.18 | +21.3% | 16.36 | 09 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 973.63 | −2.6% | 255.00 | +2.5% | 14.92 | 06 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 804.83 | −0.8% | 204.70 | +12.7% | 12.08 | 01 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 966.08 | +6.1% | 260.14 | +34.7% | 15.35 | 13 May 2025 |
| Q3 FY25Oct–Dec 2024 | 946.36 | +17.6% | 228.58 | +402.5% | 13.49 | 14 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 1,000.05 | +4.9% | 248.69 | +15.4% | 14.45 | 30 Oct 2024 |
| Q1 FY25Apr–Jun 2024 | 811.00 | +9.9% | 181.65 | +39.1% | 10.72 | 05 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 910.87 | +16.5% | 193.08 | +46.9% | 11.39 | 18 May 2024 |
| Q3 FY24Oct–Dec 2023 | 804.98 | +0.7% | 45.49 | −72.3% | 9.88 | 13 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 953.38 | +5.3% | 215.54 | +11.4% | 12.72 | 13 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 738.02 | +1.2% | 130.58 | +10.0% | 6.94 | 27 Jul 2023 |
| Q4 FY23Jan–Mar 2023 | 782.16 | −1.2% | 131.48 | −89.2% | 7.77 | 18 May 2023 |
| Q3 FY23Oct–Dec 2022 | 799.11 | −1.1% | 164.03 | +9.6% | 9.68 | 08 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 905.61 | −8.7% | 193.56 | −4.5% | 11.42 | 12 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 729.46 | −5.7% | 118.68 | −1.4% | 7.01 | 26 Jul 2022 |
| Q4 FY22Jan–Mar 2022 | 791.92 | −1.9% | 1,217.84 | 96x | 71.89 | 17 May 2022 |
| Q3 FY22Oct–Dec 2021 | 807.98 | −5.9% | 149.63 | −4.9% | 8.83 | 07 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 991.53 | +12.8% | 202.65 | +164.9% | 11.96 | 30 Oct 2021 |
| Q1 FY22Apr–Jun 2021 | 773.46 | +19.2% | 120.40 | +8.5% | 7.11 | 27 Jul 2021 |
| Q4 FY21Jan–Mar 2021 | 807.27 | +4.0% | 12.74 | −90.8% | 0.75 | 19 May 2021 |
| Q3 FY21Oct–Dec 2020 | 858.42 | +10.2% | 157.35 | Turned profit | 9.29 | 05 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 879.39 | −0.3% | 76.50 | −84.8% | 4.52 | 29 Oct 2020 |
| Q1 FY21Apr–Jun 2020 | 648.65 | −17.7% | 110.96 | −2.2% | 6.55 | 30 Jul 2020 |
| Q4 FY20Jan–Mar 2020 | 775.88 | +3.3% | 137.94 | +12.1% | 8.14 | 19 May 2020 |
| Q3 FY20Oct–Dec 2019 | 778.68 | −5.7% | (644.14) | Turned loss | (38.02) | 04 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 882.10 | +8.1% | 502.79 | +398.9% | 29.68 | 23 Oct 2019 |
| Q1 FY20Apr–Jun 2019 | 788.02 | +7.1% | 113.46 | +28.1% | 6.70 | 23 Jul 2019 |
| Q4 FY19Jan–Mar 2019 | 751.22 | — | 123.03 | — | 7.26 | 20 May 2019 |
| Q3 FY19Oct–Dec 2018 | 825.35 | — | 112.97 | — | 6.67 | 04 Feb 2019 |
| Q2 FY19Jul–Sep 2018 | 816.31 | — | 100.77 | — | 5.95 | 22 Oct 2018 |
| Q1 FY19Apr–Jun 2018 | 735.65 | — | 88.59 | — | 10.46 | 25 Jul 2018 |
63 filings on record for this company.